ArticleProceedings of the National Academy of Sciences of the United States of America2026
Artificially constructed collagen-targeting receptors on mesenchymal stromal cells promote anoikis resistance and tissue repair.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Injectable, electrosprayed RGD-coupled alginate hydrogel microcapsules enable enhanced viability and sustained release of mesenchymal stem cells.Biomedical microdevices · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Mesenchymal stem cell (MSC)-based therapy holds significant promise in regenerative medicine, leveraging their multipotent differentiation capacity and paracrine effects. However, clinical translation is limited by poor cell survival and engraftment in a hostile injury microenvironment, where detachment-induced anoikis and insufficient extracellular matrix (ECM) adhesion compromise their therapeutic efficacy. Here, we engineered MSCs with surface-anchored von Willebrand factor A3 domain (vWF A3), a natural collagen-binding domain with exceptional affinity for type I and III collagen, to simultaneously confer collagen-targeting and prosurvival functionalities. The vWF A3-modified MSCs (vWF A3-MSCs) exhibited enhanced collagen-binding capacity, improving retention in myocardial infarction (MI) and osteoarthritis (OA) lesions. Beyond adhesion, vWF A3-MSCs demonstrated improved reparative capacity and anoikis resistance, driven by the activation of ECM-receptor interaction and integrin β3 signaling. These modifications promoted proangiogenic effects via mitogen-activated protein kinase pathway activation while enhancing cell survival through Hippo pathway suppression. In vivo studies confirmed the superior therapeutic efficacy of vWF A3-MSCs in both MI and OA models, highlighting how the artificially constructed collagen-targeting receptors on cell and ECM-adhesion-targeted strategy reprogram cellular fate and enhance therapeutic efficacy in stem cell-based regenerative medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.